EyePoint Pharmaceuticals (EYPT)
11.78
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13G EyePoint, Inc. Filed by: Commodore Capital LP
June 3, 2026 4:40 PM - SEC Filing
Form 4 EyePoint, Inc. For: May 25 Filed by: Elston George
May 27, 2026 4:06 PM - SEC Filing
EyePoint Announces Participation at Upcoming Investor Conferences
May 19, 2026 7:00 AM - Globe NewsWire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 18, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Paradigm Biocapital Advisors LP
May 15, 2026 4:33 PM - SEC Filing
Form 8-K EyePoint, Inc. For: May 14
May 14, 2026 7:05 AM - SEC Filing
EyePoint gets third positive safety review for wet AMD drug trials
May 14, 2026 7:01 AM - StreetInsider
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
May 14, 2026 7:01 AM - Globe NewsWire
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Adage Capital Management, L.P.
May 13, 2026 9:05 AM - SEC Filing
Form 10-Q EyePoint, Inc. For: Mar 31
May 7, 2026 4:08 PM - SEC Filing
EyePoint Inc. (EYPT) PT Lowered to $37 at RBC Capital
May 7, 2026 8:23 AM - StreetInsider
Guggenheim Reiterates Buy Rating on EyePoint Inc. (EYPT)
May 7, 2026 3:18 AM - StreetInsider
Citi Opens 30-Day Upside Catalyst Watch on EyePoint Inc. (EYPT)
May 6, 2026 4:08 PM - StreetInsider
EyePoint Pharmaceuticals (EYPT) Misses Q1 EPS by 17c
May 6, 2026 7:06 AM - StreetInsider
Form 8-K EyePoint, Inc. For: May 06
May 6, 2026 7:05 AM - SEC Filing
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
May 6, 2026 7:00 AM - Globe NewsWire
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026 7:00 AM - Globe NewsWire
Form DEFA14A EyePoint, Inc.
April 27, 2026 4:09 PM - SEC Filing
Form DEF 14A EyePoint, Inc. For: Jun 18
April 27, 2026 4:06 PM - SEC Filing
Form 4 EyePoint, Inc. For: Apr 17 Filed by: Ribeiro Ramiro
April 20, 2026 4:09 PM - SEC Filing
Form 144 EyePoint, Inc. Filed by: Ribeiro Ramiro
April 17, 2026 4:37 PM - SEC Filing
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 16, 2026 4:01 PM - Globe NewsWire
Form 8-K EyePoint, Inc. For: Apr 13
April 13, 2026 4:05 PM - SEC Filing
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: VANGUARD GROUP INC
March 26, 2026 6:23 PM - SEC Filing
Form 4 EyePoint, Inc. For: Mar 23 Filed by: Duker Jay S.
March 24, 2026 4:06 PM - SEC Filing
Form 8-K EyePoint, Inc. For: Mar 20
March 20, 2026 4:32 PM - SEC Filing
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Form 4 EyePoint, Inc. For: Mar 16 Filed by: Duker Jay S.
March 16, 2026 4:14 PM - SEC Filing
Guggenheim Reiterates EyePoint (EYPT) at Buy, "EYPT remains one of our Top Picks"
March 16, 2026 7:52 AM - StreetInsider
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 16, 2026 7:00 AM - Globe NewsWire
Full Article List
